FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)													
Name and Address of Reporting Person * Leon Alfonzo				2. Issuer Name and Ticker or Trading Symbol Global Medical REIT Inc. [GMRE]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) 2 BETHESDA METRO CENTER, SUITE 440				3. Date of Earliest Transaction (Month/Day/Year) 03/03/2020							X Officer (give title below) Other (specify below) Chief Investment Officer				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
BETHES	SDA, MD 2	20814									Tomi med o	y Wore than One	c reporting reison		
(Cit	y)	(State)	(Zip)			Table	e I - 1	Non-Derivat	ive Securiti	es Acquired	l, Dispose	d of, or Ben	eficially Owne	d	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date, any (Month/Day/Yes		te, if Coo (Ins	(Instr. 8)		or Disposed tr. 3, 4 and 5 (A) or Dunt (D)	oosed of (D) Ownand 5) Trans (Instr				wnership of orm: Be	Nature Indirect eneficial wnership astr. 4)	
Reminder:	Report on a s	separate line for each	h class of securities	s beneficial	lly ov	wned dire	ctly								
								containe	d in this fo	rm are not	required	of inform to respon ontrol num	d unless the	SEC 147	74 (9-02)
			Table II -					ired, Disposo options, conv			wned				
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. If Transaction Code		5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and of Underly Securities (Instr. 3 and	ing		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
LTIP Unit (Right to Buy)	(2)	03/03/2020		A		16,832		(2)	(2)	Common Stock	16,832	\$ 0	91,160	D	
LTIP Unit (Right to Buy)	(2)	03/03/2020		A		5,857		(2)	(2)	Common Stock	5,857	\$ 0	97,017	D	
LTIP Unit (Right to Buy)	<u>(2)</u>	03/03/2020		A		25,974		(2)	(2)	Common Stock	25,974	\$ 0	122,991	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Leon Alfonzo 2 BETHESDA METRO CENTER, SUITE 440 BETHESDA, MD 20814			Chief Investment Officer			

Signatures

/s/ Alfonzo Leon	03/05/2020
***Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 - Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 3, 2020 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2019
- (1) and 50% of the LTIP Units will vest on March 3, 2021, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to an LTIP Unit annual award vesting agreement, the form of which was filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 7, 2019, and pursuant to the Issuer's 2016 Equity Incentive Plan.
- (2) As described in the OP's partnership agreement, vested LTIP Units that have achieved capital account parity may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.
- LTIP Units vest in equal one-third installments on March 3 of 2021, 2022 and 2023. The LTIP Units were awarded pursuant to an LTIP Unit vesting agreement, the form of which was (3) filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 5, 2020, and pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan.
- The Issuer's Board of Directors determined on March 3, 2020 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of February 28, 2020 and 50% of the LTIP Units will vest on March 3, 2021, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.3 to the Issuer's Current Report on Form 8-K filed on March 6, 2017, and pursuant to the Issuer's 2016 Equity Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.